Under AAAResearchReports.com Microscope: Pfizer Inc., Merck & Co. Inc., AbbVie Inc., and Zogenix Inc. Editor Note: For more information about this release, please scroll to bottom. PR Newswire LONDON, October 4, 2013 LONDON, October 4, 2013 /PRNewswire/ -- The U.S. equity market ended the day lower on Thursday, October 3, 2013. The Dow Jones Industrial Average closed at 14,996.48, down 0.90%; the S&P 500 closed at 1,678.66, down 0.90%; and the NASDAQ Composite finished at 3,774.34, down 1.07%. Shares in the drug manufacturing industry ended on a mixed note, even as the broader market posted losses. The major movers in the industry included Pfizer Inc. (NYSE: PFE), Merck and Company Inc. (NYSE: MRK), AbbVie Inc. (NYSE: ABBV), and Zogenix Inc. (NASDAQ: ZGNX). AAAResearchReports.com has released full comprehensive research on PFE, MRK, ABBV, and ZGNX. These free technical analyses can be downloaded by signing up at: http://www.aaaresearchreports.com/register/ Pfizer Inc.'s shares fell by 0.83% on Thursday, tracking losses in the broader market. The company's shares oscillated between$28.69 and $29.02before ending the day at$28.77. A total of 22.69 million shares were traded, which is below the daily average volume of 27.15 million. Despite Thursday's decline, the company's shares have gained 4.05% in the previous three months and 2.71% in the last one month, compared to a gain of 3.92% and 2.37% in the S&P 500 during the respective periods. Moreover, Pfizer Inc.'s stock is currently trading above its 50-day moving average of $28.53. A free technical analysis on PFE available by signing up at: http://www.AAAResearchReports.com/PFE100413.pdf Shares in Merck and Co. Inc. fluctuated between gains and losses before finishing the day nearly flat on Thursday. The company's shares ended the day at$48.36, down 0.02%, after fluctuating between$48.00 and$48.75 during the trading session. A total of 17.90 million shares were traded, which is above the daily average volume of 12.16 million. The company's shares have advanced 1.58% in the last three trading sessions and 2.44% in the previous one month, compared to a loss of 0.17% and a gain of 2.37% in the S&P 500 during the respective periods. Further, Merck and Co. Inc.'s stock is trading above its 50-day and 200-day moving averages of $47.77 and $47.13, respectively. Register today and access free research on MRK at: http://www.AAAResearchReports.com/MRK100413.pdf On Thursday, AbbVie Inc.'s stock advanced to close at $46.01, up 0.13% from the previous day's closing price of $45.95. The company's shares oscillated between $45.10 and $46.34 during the trading session. A total of 7.02 million shares were traded, which is above the daily average volume of 4.04 million. The company's shares are up 8.03% in the previous one month and 8.95% in the last three months, compared to a gain of 2.37% and 3.92% in the S&P 500 during the respective periods. Additionally, AbbVie Inc.'s stock is trading above its 50-day and 200-day moving averages of $44.50 and $43.75, respectively. The free report on ABBV can be downloaded by signing up now at: http://www.AAAResearchReports.com/ABBV100413.pdf On Thursday, shares in Zogenix Inc. rallied 11.61%, extending the gains from the previous trading session. The company's shares ended the day at $2.50 after vacillating between$2.25 and $2.65 during the trading session. A total of 3.78 million shares were traded, which is above the daily average volume of 0.54 million. The company's stock has surged 63.40% in the previous three months and 39.66% in the last one month, outperforming the S&P 500 which has advanced 3.92% and 2.37% during the respective periods. Furthermore, Zogenix Inc.'s stock is trading above its 50-day and 200-day moving averages of $1.79 and $1.66, respectively. A free report on ZGNX can be accessed by registering at: http://www.AAAResearchReports.com/ZGNX100413.pdf ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AAAresearchreports.com SOURCE AAA Research Reports Contact: +1(646)396-9126, Peter F. Jones, email@example.com
Under AAAResearchReports.com Microscope: Pfizer Inc., Merck & Co. Inc., AbbVie Inc., and Zogenix Inc.